Clinical trial
Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in…
NCT00439166 · Hamilton Health Sciences Corporation, Other · Completed
Key facts
| NCT number | NCT00439166 |
|---|---|
| Title | Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid |
| Official title | Effects of Treatment With Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid |
| Lead sponsor | Hamilton Health Sciences Corporation, Other |
| Collaborators | The Physicians' Services Incorporated Foundation |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | doxycycline, rifampicin, Placebo matched to doxycycline, Placebo matched to Rifampin |
| Enrollment | 100 |
| Start date | Feb 1, 2007 |
| Primary completion | Apr 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Feb 23, 2007 |
| Last update posted | Mar 19, 2018 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: